A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer
Latest Information Update: 27 Apr 2025
At a glance
- Drugs Carboplatin (Primary) ; Osimertinib (Primary) ; Pembrolizumab (Primary) ; Sacituzumab Tirumotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Klus Pharma
Most Recent Events
- 12 Sep 2024 Planned number of patients changed from 278 to 498.
- 12 Sep 2024 Planned End Date changed from 31 Aug 2026 to 30 Oct 2026.
- 19 Jun 2024 Planned number of patients changed from 296 to 278.